UNSPSC 51263117: Carazolol

This classification denotes a beta-adrenergic blocking agent with the molecular formula C18H22N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 29PW75S82A, chemically known as 2-propanol, 1-(9h-carbazol-4-yloxy)-3-((1-methylethyl)amino)- but generally known as carazolol, which bears US NIH Compound Identifier 71739. Carazolol most often comes in base, glucuronide, and hydrochloride forms. European Medicines Agency schedules Carazolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06086MIG.

UNSPSC 51263117 Carazolol is a Commodity code that in practice covers pharmaceutical products and drug-related procurement by state and local health and human services agencies. Recent solicitations under this code show state and local governments purchasing naloxone, drug deactivation systems, and related pharmaceutical supplies to support community health and pharmacy benefit initiatives. The issuing bodies include county health departments and state health and human services commissions, with a focus on acquiring medications and medical supplies to support public health programs and prescription management operations.

Activity under the code concentrates in Florida and Texas. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, with a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor information on direct-to-manufacturer prescription programs and pharmacy benefit capabilities, signaling early-stage market research ahead of a formal solicitation. Both opportunities reflect state and local focus on supply chain efficiency and cost management in pharmaceutical procurement.